Common use of Transfer of Obligation Clause in Contracts

Transfer of Obligation. See Work Statement NB-1 Attachment C. Attachment 2, Attachment H-1 Attachment 3 Form of Enterprise CTA CLINICAL TRIAL AGREEMENT Protocol No. BA058-05-003 This Clinical Trial Agreement (“Agreement”) is entered into by and among CENTER FOR CLINICAL AND BASIC RESEARCH A/S, Xxxxxxxxxxx 0, 0, 0000 Xxxxxxxx, Xxxxxxx (“CCBR”) on behalf of itself and its ten [affiliated][controlled] Clinical Study Sites listed below and Nordic Bioscience A/S, Xxxxxx Xxxxxxxxx 000, 0000 Xxxxxx, Xxxxxxx (“Nordic Bioscience”), representing the interests of Radius Health, Inc. (“Sponsor”) concerning: Protocol No. BA058-05-003, “A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 (“Study Drug”) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of Fracture” (together with any of its subsequent amendments, the “Protocol”), which will guide the performance of the Study, has been prepared by Radius and Nordic Bioscience and accepted by the Clinical Study Sites. CCBR has the legal authority to bind the following clinical study sites (the “Clinical Study Site(s)”):

Transfer of Obligation. See Work Statement NB-1 Attachment C. Attachment 2, Attachment H-1 Attachment 3 Form of Enterprise CTA CLINICAL TRIAL AGREEMENT Protocol No. BA058-05-003 This Clinical Trial Agreement (“Agreement”) is entered into by and among CENTER FOR CLINICAL AND BASIC RESEARCH A/S, Xxxxxxxxxxx 0, 0, 0000 Xxxxxxxx, Xxxxxxx (“CCBR”) on behalf of itself and its ten [affiliated][controlled] Clinical Study Sites listed below and Nordic Bioscience A/S, Xxxxxx Herlev Xxxxxxxxx 000, 0000 Xxxxxx, Xxxxxxx (“Nordic Bioscience”), representing the interests of Radius Health, Inc. (“Sponsor”) concerning: Protocol No. BA058-05-003, “A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 (“Study Drug”) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of Fracture” (together with any of its subsequent amendments, the “Protocol”), which will guide the performance of the Study, has been prepared by Radius Xxxxxx and Nordic Bioscience and accepted by the Clinical Study Sites. CCBR has the legal authority to bind the following clinical study sites (the “Clinical Study Site(s)”):